Chlamydial Antibodies and Risk of Prostate Cancer

Objective: We assessed the risk of prostate cancer by exposure to Chlamydia trachomatis. Method: Seven hundred thirty eight cases of prostate cancer and 2,271 matched controls were identified from three serum sample banks in Finland, Norway, and Sweden by linkage to the population based cancer registries. Results: A statistically significant inverse association (odds ratio, 0.69; 95% confidence interval, 0.51-0.94) was found. It was consistent by different serotypes and there was a consistent dose-response relationship. Conclusion: C. trachomatis infection is not likely to increase the risk of prostate cancer. Whether the inverse relationship is true or due to difficulties in measuring the true exposure in prostatic tissue by serology, confounders or other sources of error remain open.

[1]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[2]  I. Bravo,et al.  Papillomaviruses , 2006, Journal of Cancer Research and Clinical Oncology.

[3]  M. Leinonen,et al.  Association between Chlamydia trachomatis antibodies and subfertility in the Northern Finland Birth Cohort 1966 (NFBC 1966), at the age of 31 years , 2004, Epidemiology and Infection.

[4]  P. Stattin,et al.  High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study , 2004, International journal of cancer.

[5]  O. Ogawa.  Risk Factors for Prostate Cancer , 2004 .

[6]  L. Kolonel.  Nutrition and prostate cancer , 2004, Cancer Causes & Control.

[7]  D. English,et al.  Sexual factors and prostate cancer , 2003, BJU international.

[8]  Christian Munk,et al.  Comparison of Three Commercially Available Peptide-Based Immunoglobulin G (IgG) and IgA Assays to Microimmunofluorescence Assay for Detection of Chlamydia trachomatis Antibodies , 2002, Journal of Clinical Microbiology.

[9]  Bjørn Møller,et al.  Prediction of cancer incidence in the Nordic countries up to the year 2020. , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[10]  R. Peeling,et al.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Saikku,et al.  Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. , 2001, JAMA.

[12]  B. Krausse-Opatz,et al.  Infection of Human Monocyte-Derived Macrophages with Chlamydia trachomatis Induces Apoptosis of T Cells: a Potential Mechanism for Persistent Infection , 2000, Infection and Immunity.

[13]  L. Signorello,et al.  Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. , 2000, Cancer research.

[14]  P. Lange,et al.  Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. , 2000, The Journal of urology.

[15]  J. Boman,et al.  Comparison of Five Serologic Tests for Diagnosis of Acute Infections by Chlamydia pneumoniae , 2000, Clinical Diagnostic Laboratory Immunology.

[16]  W. Ledger,et al.  Detection of Chlamydial Antigenic Material in Ovarian, Prostatic, Ectopic Pregnancy and Semen Samples of Culture‐Negative Subjects , 2000, American journal of reproductive immunology.

[17]  T. Bjørge,et al.  Chlamydia trachomatis infection as a risk factor for invasive cervical cancer , 2000, International journal of cancer.

[18]  T. Olsson,et al.  Leptin is associated with increased risk of myocardial infarction , 1999, Journal of internal medicine.

[19]  W. Nelson,et al.  Prostate cancer vaccines: current status. , 1999, Seminars in oncology.

[20]  H. Rabenau,et al.  Chlamydia trachomatis and male infertility: chlamydia‐IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response 1 , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  B. Baban,et al.  Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). , 1998, British journal of urology.

[22]  M. Lehtinen,et al.  Sero‐epidemiologal association between human‐papillomavirus infection and risk of prostate cancer , 1998 .

[23]  Boman,et al.  Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case–control study from northern Sweden , 1998, Journal of internal medicine.

[24]  M. Lehtinen,et al.  Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. , 1998, International journal of cancer.

[25]  R. Kelly.  Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[26]  D. Albanes,et al.  Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer , 1997, International journal of cancer.

[27]  W. M. Mac Kenzie,et al.  Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. , 1997, American journal of obstetrics and gynecology.

[28]  M. Lehtinen,et al.  Chlamydial pelvic inflammatory disease. , 1996, Human reproduction update.

[29]  M. Stampfer,et al.  Prospective study of sex hormone levels and risk of prostate cancer. , 1996, Journal of the National Cancer Institute.

[30]  O. Zimmermann,et al.  Chlamydia trachomatis antibodies in serum and ejaculate of male patients without acute urethritis. , 1996, Annales d'urologie.

[31]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[32]  A. Andersen,et al.  Experiences of the Janus Serum Bank in Norway. , 1995, Environmental health perspectives.

[33]  J. Mahony,et al.  Chlamydial immunoglobulin IgG and IgA antibodies in serum and semen are not associated with the presence of Chlamydia trachomatis DNA or rRNA in semen from male partners of infertile couples. , 1995, Human reproduction.

[34]  S. Pekka,et al.  Diagnosis of acute and chronic Chlamydia pneumoniae infections , 1995 .

[35]  F. Grodstein,et al.  Prospective study of plasma fatty acids and risk of prostate cancer. , 1994, Journal of the National Cancer Institute.

[36]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[37]  G. Greendale,et al.  The relationship of Chlamydia trachomatis infection and male infertility. , 1993, American journal of public health.

[38]  R. Peto,et al.  Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. , 1993, American journal of epidemiology.

[39]  A. Engeland,et al.  Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries. , 1993, APMIS. Supplementum.

[40]  K. James,et al.  Immunosuppression by Human Seminal Plasma&—Extracellular Organelles (Prostasomes) Modulate Activity of Phagocytic Cells , 1992, American journal of reproductive immunology.

[41]  J. Tuomilehto,et al.  The prevalence and regional distribution of antibodies against Chlamydia pneumoniae (strain TWAR) in Finland in 1958. , 1992, International journal of epidemiology.

[42]  L. Kolonel,et al.  Prostate cancer: a current perspective. , 1991, Epidemiologic reviews.

[43]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[44]  M. Toni,et al.  Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis. , 1985, The Journal of urology.

[45]  B. Henderson,et al.  The etiology of prostate cancer: What does the epidemiology suggest? , 1983, The Prostate.

[46]  M. O'Shaughnessy,et al.  The role of chlamydiae in genitourinary disease. , 1981, The Journal of urology.

[47]  K. Magnus,et al.  Trends in Cancer Incidence: Causes and Practical Implications , 1981 .

[48]  L Weström,et al.  Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. , 1980, American journal of obstetrics and gynecology.

[49]  S. Colleen,et al.  Inhibitory effect on the formation of chlamydial inclusions in McCoy cells by seminal fluid and some of its components. , 1980, Investigative urology.

[50]  P. Mårdh,et al.  Chlamydia in chronic prostatitis. , 1972, British medical journal.